TrialBlood advances2023

Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia.

Danielle S Wallace et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.